by What is the Viral and Non-Viral Vectors Market Size in 2026?
The global viral and non-viral vectors market was valued at USD 9.40 billion in 2025 and is projected to grow from USD 11.07 billion in 2026 to USD 48.37 billion by 2035, registering a CAGR of 17.80% during the forecast period from 2026 to 2035.
Key Takeaways
- North America led the viral and non-viral vectors market in 2025 with a 45% share.
- Asia Pacific is observed to grow at the fastest CAGR of 22.5% during the forecast period.
- By vector type, the viral vectors segment led the market with a 70% share in 2025.
- By vector type, the non-viral vectors segment is expected to grow at the fastest CAGR of 22.5% in the upcoming period.
- By disease indication, the oncology segment led the global market in 2025 with a 40% share and is expected to grow at the fastest CAGR of 19% in the foreseeable period.
- By application, the gene therapy segment led the global market in 2025 with a 35% share.
- By application, the cell therapy segment is expected to grow at the fastest CAGR of 20% in the coming years.
- By end-use, the pharmaceutical & biotechnology companies segment led the global market in 2025 with a 50% share.
- By end-use, the CROS/CDMOS segment is observed to expand at the fastest CAGR of 20.5% in the upcoming period.
- By delivery mode, the in vivo gene delivery segment led the global market in 2025 with a 55% share and is expected to grow at the fastest CAGR of 18.5% over the forecast period.
Impact of Artificial Intelligence on the Viral and Non-Viral Vectors Market
Artificial intelligence (AI) is playing a pivotal role in improving treatment efficiency across the healthcare sector. AI-powered models and algorithms are enabling the development of advanced targeted gene delivery systems capable of overcoming extracellular and intracellular barriers by leveraging mechanisms that mimic viral behavior. The integration of AI with viral and non-viral vector platforms is expected to accelerate the development of safer, more effective, and consistently administered gene therapies, offering significant potential for the treatment of a wide range of genetic and acquired disorders.
Viral and Non-Viral Vectors Market Overview
Viral vectors are engineered from viruses and leverage their natural ability to enter cells and deliver genetic material directly into the nucleus. Non-viral vectors, on the other hand, include naked DNA, particle-based carriers, and chemical-based delivery systems. These vectors can be introduced through direct plasmid or naked DNA delivery, as well as various chemical and physical transfection techniques.
Viral transfection is widely preferred due to its high efficiency, strong specificity, and effectiveness in difficult-to-transfect cells, while also offering relatively lower operational complexity and cost. However, non-viral approaches provide significant advantages in terms of safety, reduced immunogenicity, and greater flexibility for targeting specific cell types and diseases. The complementary benefits of both vector types are driving innovation and creating substantial growth opportunities in the viral and non-viral vectors market.
Market Scope
| Report Coverage | Details |
| Market Size in 2025 | USD 9.40 Billion |
| Market Size in 2026 | USD 11.07 Billion |
| Market Size by 2035 | USD 48.37 Billion |
| Market Growth Rate from 2026 to 2035 | CAGR of 17.80% |
| Dominating Region | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
Regional Insights
North America Viral and Non-Viral Vectors Market Size and Growth 2026 to 2035
The North America viral and non-viral vectors market size was valued at USD 4.23 billion in 2025 and is projected to grow to approximately USD 22.01 billion by 2035, expanding at a CAGR of 17.93% during the forecast period from 2026 to 2035.
North America Dominated the Market with a 45% Share in 2025
In 2025, North America dominated the viral and non-viral vectors market, capturing 45% share in 2025. This dominance is attributed to a strong pipeline of gene therapies, significant funding, and the presence of leading biotech companies. Additionally, the region’s dominance is bolstered by substantial research and development investments, a high number of clinical trials, and favorable regulatory environments.
Asia Pacific: The Fastest-Growing Region
Asia Pacific held a 18% share of the viral and non-viral vectors market in 2025 and is expected to grow at a CAGR of 22.5% throughout the forecast period. This growth is primarily fueled by a rise in clinical trials, expansion in manufacturing, and robust government support. Additionally, the regional market benefits from industrialization, increased manufacturing activities, digital transformation, strong demand from emerging economies, and ongoing urbanization. Enhanced research initiatives and a growing prevalence of clinical trials further contribute to this market expansion.
Application Insights
Why Did the Gene Therapy Segment Dominate the Market in 2025?
The gene therapy segment accounted for the largest share of the viral and non-viral vectors market, capturing 35% of the market in 2025. This dominance is driven by the growing number of gene therapy approvals and the continued expansion of the development pipeline. Gene therapy works by replacing defective genes, silencing disease-causing genes, or introducing functional copies of genes to treat various conditions. Additionally, many gene therapies are designed as one-time treatments rather than requiring long-term medication, enhancing their clinical and economic value and supporting the segment’s continued market leadership.
Viral and Non-Viral Vectors Market Companies
- Charles River Laboratories International, Inc.: Charles River Laboratories provides drug discovery, preclinical testing, and manufacturing support services for the biopharmaceutical industry.
The company offers viral vector development and gene therapy solutions that help accelerate the advancement of innovative treatments. - Takara Bio Inc.: Takara Bio specializes in biotechnology products and services focused on gene therapy, cell therapy, and molecular biology research.
Its portfolio includes viral vector manufacturing technologies and research tools that support advanced therapeutic development. - GenScript Biotech Corporation: GenScript Biotech is a leading life sciences company providing gene synthesis, biologics development, and cell and gene therapy services.
The company supports researchers with plasmid DNA production, viral vector manufacturing, and custom biotechnology solutions. - Creative Biogene: Creative Biogene offers specialized gene therapy research services, including vector design, construction, and packaging.
Its solutions support academic institutions and biotechnology companies engaged in gene and cell therapy development. - VectorBuilder Inc.: VectorBuilder provides custom vector design and gene delivery services for biomedical research and therapeutic applications.
The company is recognized for its extensive vector platform and viral vector manufacturing capabilities. - Aldevron: Aldevron develops and manufactures high-quality plasmid DNA, mRNA, proteins, and gene-editing components.
The company plays a critical role in supporting the production of cell therapies, gene therapies, and genetic vaccines. - Merck KGaA: Merck KGaA provides bioprocessing technologies, viral vector manufacturing solutions, and gene therapy development services.
Its advanced life science platforms help researchers and manufacturers improve the efficiency and scalability of therapeutic production.
Check this report to: ICU ECG Patient Market
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview: https://www.precedenceresearch.com/sample/8373
You can place an order or ask any questions. Please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344
